肾性贫血是慢性肾脏病（CKD）患者常见的并发症。为帮助公众更好地认识这一疾病，解放军总 医院蔡广研、复旦大学附属中山医院丁小强、上海交通大学医学院附属新华医院蒋更如在"人民好医 生"科普直播间，就肾性贫血的防治进行了深入解读。 肾性贫血的发病机制与危害 肾性贫血是慢性肾脏病患者常见的并发症，其发病机制与普通贫血不同，主要与肾脏功能受损密切 相关。蔡广研谈到，肾脏是促红细胞生成素（EPO）的主要生成器官，当肾功能下降时，EPO合成减 少，导致骨髓造血功能受抑制，红细胞生成不足。此外，尿毒症毒素蓄积会破坏红细胞膜稳定性，缩短 红细胞寿命，进一步加重贫血。 蔡广研提出，与其他类型贫血不同，肾性贫血与肾脏疾病直接相关，且危害更大。若不及时干预， 长期贫血会导致组织缺氧，加速肾功能恶化，形成恶性循环。同时，贫血会增加心脏负担，诱发或加重 左心室肥厚、心力衰竭等心血管并发症，显著提高患者的心血管事件风险及死亡率。 丁小强表示，首先，口服给药提高依从性，减少了患者的治疗负担，尤其适合长期管理的慢性肾脏 病患者；其次，HIF-PHI不仅促进内源性EPO生成，还能改善铁的吸收和利用，同时减轻慢性炎症对造 血功能的抑制，从多个环 ...

Core Viewpoint - Renal anemia is a common complication in chronic kidney disease (CKD) patients, significantly affecting their quality of life and increasing the risk of cardiovascular events and mortality [1] Group 1: Disease Overview - Approximately 50% of CKD patients in China experience anemia, with incidence rates rising as kidney function deteriorates [1] - The underlying causes of renal anemia include insufficient erythropoietin (EPO) production, iron metabolism disorders, and inflammation [1] - Symptoms of renal anemia include fatigue, palpitations, and reduced exercise tolerance [1] Group 2: Treatment Challenges - Current treatment options include iron supplementation, erythropoiesis-stimulating agents (ESA), and oral HIF-PHI drugs [1] - Patients face challenges such as iron deficiency, ESA resistance, and poor treatment adherence [1] - Some patients delay diagnosis and treatment due to a lack of awareness or reliance on blood transfusions [1] Group 3: Expert Insights - A live session featuring experts in nephrology will be held to discuss the standardized diagnosis and treatment of renal anemia, aiming to help patients and families respond scientifically and improve quality of life [1][2]